Develops immunotherapies for cancer and inflammatory diseases, focusing on modulating the immune system to enhance anti-tumor responses.
INmune Bio, Inc., a pioneering clinical-stage immunotherapy company based in Boca Raton, Florida, specializes in harnessing and reprogramming the innate immune system to combat cancer, Alzheimer's disease, and non-alcoholic steatohepatitis (NASH). The company is dedicated to advancing a robust pipeline of product candidates aimed at treating hematologic malignancies, solid tumors, and chronic inflammatory conditions.
Among its innovative development programs, INmune Bio focuses on INKmune for relapse refractory ovarian carcinoma and high-risk myelodysplastic syndrome, INB03 targeting advanced cancers with elevated biomarkers of inflammation, and XPro1595 designed for Alzheimer's disease treatment. Additionally, the company is developing LivNate for NASH and Quellor to address cytokine release syndrome and complications associated with COVID-19.
INmune Bio has strategically partnered through license agreements with entities like Xencor, Inc., Immune Ventures, LLC, University of Pittsburgh, and University College London, enhancing its research capabilities and expanding its therapeutic reach. Since its inception in 2015, INmune Bio has remained at the forefront of immunotherapy innovation, striving to deliver novel treatment options that improve patient outcomes across a spectrum of challenging diseases.